Silence Therapeutics (SLN) News Today $6.51 -0.23 (-3.41%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Silence Therapeutics plc (NASDAQ:SLN) Receives Consensus Rating of "Buy" from AnalystsShares of Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) have been assigned an average recommendation of "Buy" from the six ratings firms that are covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price objeDecember 14, 2024 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Short Interest UpdateSilence Therapeutics plc (NASDAQ:SLN - Get Free Report) was the target of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 702,300 shares, an increase of 84.1% from the November 15th total of 381,500 shares. Based on an average daily volume of 403,300 shares, the days-to-cover ratio is presently 1.7 days.December 12, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Receives "Buy" Rating from Chardan CapitalDecember 11, 2024 | americanbankingnews.comSilence Therapeutics announces additional results from SANRECO studyDecember 10, 2024 | markets.businessinsider.comChardan Capital Reaffirms Buy Rating for Silence Therapeutics (NASDAQ:SLN)Chardan Capital restated a "buy" rating and issued a $55.00 price objective on shares of Silence Therapeutics in a report on Tuesday.December 10, 2024 | marketbeat.comSilence Therapeutics' (SLN) "Buy" Rating Reiterated at HC WainwrightDecember 10, 2024 | americanbankingnews.comSilence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual MeetingDecember 9, 2024 | businesswire.comPoint72 Asset Management L.P. Buys 321,300 Shares of Silence Therapeutics plc (NASDAQ:SLN)Point72 Asset Management L.P. lifted its stake in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 219.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 467,800 shares of tDecember 8, 2024 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Shares Purchased by Janus Henderson Group PLCJanus Henderson Group PLC raised its position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 32.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,087,228 shares of the company's stock after purchasing an addDecember 8, 2024 | marketbeat.comRedmile Group LLC Has $34.53 Million Stake in Silence Therapeutics plc (NASDAQ:SLN)Redmile Group LLC lowered its stake in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 5.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,899,317 shares of the company's stock after selling 114,979December 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Boosts Stock Holdings in Silence Therapeutics plc (NASDAQ:SLN)Parkman Healthcare Partners LLC raised its stake in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 71.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 497,870 shares of the company's stoDecember 4, 2024 | marketbeat.com640,000 Shares in Silence Therapeutics plc (NASDAQ:SLN) Bought by Eventide Asset Management LLCEventide Asset Management LLC bought a new position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 640,000 shares of the company's stock, valued at approximately $11,635,00November 29, 2024 | marketbeat.comSilence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | finance.yahoo.comSilence Therapeutics weakness after AHA updates ‘overdone,’ says BMO CapitalNovember 20, 2024 | markets.businessinsider.comSilence Therapeutics' Zerlasiran Has Competitive Concerns: AnalystNovember 19, 2024 | benzinga.comSilence Therapeutics plc (NASDAQ:SLN) Given Consensus Recommendation of "Buy" by BrokeragesShares of Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) have earned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average twelve-month tNovember 19, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Receives "Outperform" Rating from William BlairWilliam Blair reiterated an "outperform" rating on shares of Silence Therapeutics in a report on Tuesday.November 19, 2024 | marketbeat.comSilence Therapeutics presents late-breaking Phase 2 zerlasiran data at AHANovember 19, 2024 | markets.businessinsider.comSilence Therapeutics Showcases Promising Phase 2 ResultsNovember 19, 2024 | markets.businessinsider.comSilence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual MeetingNovember 18, 2024 | businesswire.comSilence Therapeutics (NASDAQ:SLN) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $75.00 price objective on shares of Silence Therapeutics in a research report on Friday.November 15, 2024 | marketbeat.comSilence Therapeutics plc: Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 14, 2024 | finanznachrichten.deSilence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare ConferenceNovember 14, 2024 | finance.yahoo.comIs Silence Therapeutics plc (SLN) a Promising Gene Editing Stock?October 31, 2024 | uk.finance.yahoo.comSilence Therapeutics (SLN) Gets a Buy from Morgan StanleyOctober 22, 2024 | markets.businessinsider.comCubist Systematic Strategies LLC Has $179,000 Position in Silence Therapeutics plc (NASDAQ:SLN)Cubist Systematic Strategies LLC lowered its holdings in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 74.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,438 shares of the company's stock after sellingOctober 15, 2024 | marketbeat.comRenaissance Technologies LLC Sells 64,800 Shares of Silence Therapeutics plc (NASDAQ:SLN)Renaissance Technologies LLC cut its position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 62.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,100 shares of the company's stock after selliOctober 9, 2024 | marketbeat.comMorgan Stanley Reaffirms Overweight Rating for Silence Therapeutics (NASDAQ:SLN)Morgan Stanley reiterated an "overweight" rating and issued a $49.00 target price on shares of Silence Therapeutics in a report on Tuesday.October 8, 2024 | marketbeat.comMillennium Management LLC Buys 373,523 Shares of Silence Therapeutics plc (NASDAQ:SLN)Millennium Management LLC raised its holdings in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 91.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 782,941 shares of the company's sOctober 7, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Stock Price Down 3.7% - Here's What HappenedSilence Therapeutics (NASDAQ:SLN) Stock Price Down 3.7% - What's Next?October 4, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Trading 3.6% Higher Silence Therapeutics (NASDAQ:SLN) Shares Up 3.6%October 3, 2024 | marketbeat.comPoint72 Asset Management L.P. Raises Stock Holdings in Silence Therapeutics plc (NASDAQ:SLN)Point72 Asset Management L.P. lifted its holdings in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 1,686.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 146,500 shares of the company's stock after purchasing aOctober 3, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Sees Large Volume IncreaseSilence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading VolumeSeptember 25, 2024 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) is M28 Capital Management LP's 6th Largest PositionM28 Capital Management LP lowered its position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 38.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 185,100 shares of the company's stock after selliSeptember 21, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading VolumeSilence Therapeutics (NASDAQ:SLN) Sees Strong Trading VolumeSeptember 17, 2024 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Sees Significant Drop in Short InterestSilence Therapeutics plc (NASDAQ:SLN - Get Free Report) saw a large drop in short interest during the month of August. As of August 31st, there was short interest totalling 254,600 shares, a drop of 27.4% from the August 15th total of 350,500 shares. Based on an average daily trading volume, of 222,600 shares, the days-to-cover ratio is presently 1.1 days.September 14, 2024 | marketbeat.com537,338 Shares in Silence Therapeutics plc (NASDAQ:SLN) Acquired by First Turn Management LLCFirst Turn Management LLC acquired a new position in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 537,338 shares of the company's stockSeptember 13, 2024 | marketbeat.comNicholas Investment Partners LP Takes $2.86 Million Position in Silence Therapeutics plc (NASDAQ:SLN)Nicholas Investment Partners LP purchased a new stake in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 150,480 shares of the company's stock, valued at approximately $2September 12, 2024 | marketbeat.comSilence: Additional siRNA Drug Data Leads To Next Stages Of DevelopmentSeptember 5, 2024 | seekingalpha.comSilence Therapeutics (NASDAQ:SLN) Now Covered by Analysts at Jefferies Financial GroupJefferies Financial Group began coverage on Silence Therapeutics in a research note on Tuesday. They issued a "buy" rating and a $40.00 price objective on the stock.September 3, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Friday.August 30, 2024 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Short Interest Down 37.5% in AugustSilence Therapeutics plc (NASDAQ:SLN - Get Free Report) was the target of a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 350,500 shares, a drop of 37.5% from the July 31st total of 561,200 shares. Based on an average trading volume of 212,000 shares, the short-interest ratio is currently 1.7 days.August 28, 2024 | marketbeat.comLegato Capital Management LLC Takes $376,000 Position in Silence Therapeutics plc (NASDAQ:SLN)Legato Capital Management LLC bought a new position in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 19,800 shares of the company's stock, valued atAugust 27, 2024 | marketbeat.comSilence Therapeutics to Webcast Presentations at Upcoming September Investor ConferencesAugust 27, 2024 | businesswire.comSilence Therapeutics (NASDAQ:SLN) Trading 4.6% Higher Silence Therapeutics (NASDAQ:SLN) Trading Up 4.6%August 26, 2024 | marketbeat.comBuy Rating Affirmed for Silence Therapeutics Amid Strong Pipeline Progress and Strategic PartnershipsAugust 16, 2024 | markets.businessinsider.comAnalyst Expectations For Silence Therapeutics's FutureAugust 16, 2024 | benzinga.comChardan Capital Reiterates Buy Rating for Silence Therapeutics (NASDAQ:SLN)Chardan Capital reaffirmed a "buy" rating and set a $55.00 target price on shares of Silence Therapeutics in a research note on Friday.August 16, 2024 | marketbeat.comAnalysts Conflicted on These Healthcare Names: MiNK Therapeutics (INKT), Silence Therapeutics (SLN) and Mersana Therapeutics (MRSN)August 16, 2024 | markets.businessinsider.comSLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024August 15, 2024 | investorplace.com Get Silence Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter. Email Address Forbes rich list released… #1 to be assassinated? (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now SLN Media Mentions By Week SLN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLN News Sentiment▼0.440.71▲Average Medical News Sentiment SLN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLN Articles This Week▼32▲SLN Articles Average Week Get Silence Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AVXL News IMNM News KURA News KROS News TYRA News ERAS News CRON News EOLS News DNTH News RAPP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLN) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Silence Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
